Energy Metabolites as Biomarkers in Ischemic and Dilated Cardiomyopathy

Energy Metabolites as Biomarkers in Ischemic and Dilated Cardiomyopathy. Haas, J., Frese, K., Sedaghat-Hamedani, F., Kayvanpour, E., Tappu, R., Nietsch, R., Tugrul, O., Wisdom, M., Dietrich, C., Amr, A., Weis, T., Niederdränk, T., Murphy, M., Krieg, T., Dörr, M., Völker, U., Fielitz, J., Frey, N., Felix, S. B., Keller, A., Katus, H. A., & Meder, B. International Journal of Molecular Sciences, 22:1999, 02, 2021.

Paper doi abstract bibtex

With more than 25 million people affected, heart failure (HF) is a global threat. As energy production pathways are known to play a pivotal role in HF, we sought here to identify key metabolic changes in ischemic- and non-ischemic HF by using a multi-OMICS approach. Serum metabolites and mRNAseq and epigenetic DNA methylation profiles were analyzed from blood and left ventricular heart biopsy specimens of the same individuals. In total we collected serum from n = 82 patients with Dilated Cardiomyopathy (DCM) and n = 51 controls in the screening stage. We identified several metabolites involved in glycolysis and citric acid cycle to be elevated up to 5.7-fold in DCM (p = 1.7 × 10−6). Interestingly, cardiac mRNA and epigenetic changes of genes encoding rate-limiting enzymes of these pathways could also be found and validated in our second stage of metabolite assessment in n = 52 DCM, n = 39 ischemic HF and n = 57 controls. In conclusion, we identified a new set of metabolomic biomarkers for HF. We were able to identify underlying biological cascades that potentially represent suitable intervention targets.

@article{haas211,
    author = {Haas, Jan and Frese, Karen and Sedaghat-Hamedani, Farbod and Kayvanpour, Elham and Tappu, Rewati and Nietsch, Rouven and Tugrul, Oguz and Wisdom, Michael and Dietrich, Carsten and Amr, Ali and Weis, Tanja and Niederdränk, Torsten and Murphy, Michael and Krieg, Thomas and Dörr, Marcus and Völker, Uwe and Fielitz, Jens and Frey, Norbert and Felix, Stephan B. and Keller, Andreas and Katus, Hugo A. and Meder, Benjamin},
    year = {2021},
    month = {02},
    pages = {1999},
    title = {Energy Metabolites as Biomarkers in Ischemic and Dilated Cardiomyopathy},
    volume = {22},
    journal = {International Journal of Molecular Sciences},
    doi = {10.3390/ijms22041999},
	abstract = {With more than 25 million people affected, heart failure (HF) is a global threat. As energy production pathways are known to play a pivotal role in HF, we sought here to identify key metabolic changes in ischemic- and non-ischemic HF by using a multi-OMICS approach. Serum metabolites and mRNAseq and epigenetic DNA methylation profiles were analyzed from blood and left ventricular heart biopsy specimens of the same individuals. In total we collected serum from n = 82 patients with Dilated Cardiomyopathy (DCM) and n = 51 controls in the screening stage. We identified several metabolites involved in glycolysis and citric acid cycle to be elevated up to 5.7-fold in DCM (p = 1.7 × 10−6). Interestingly, cardiac mRNA and epigenetic changes of genes encoding rate-limiting enzymes of these pathways could also be found and validated in our second stage of metabolite assessment in n = 52 DCM, n = 39 ischemic HF and n = 57 controls. In conclusion, we identified a new set of metabolomic biomarkers for HF. We were able to identify underlying biological cascades that potentially represent suitable intervention targets.},
	URL = {https://www.mdpi.com/1422-0067/22/4/1999},
}

Downloads: 0